1 / 5

Patent issue

Patent issue . Discovery of a new aspect of TNF- α -related signaling. Currently known to causes apoptotic cell death, cellular proliferation, differentiation, inflammation, and viral replication promoting various aspects of immunity and inflammation

shadow
Download Presentation

Patent issue

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Patent issue

  2. Discovery of a new aspect of TNF-α-related signaling • Currently known to causes apoptotic cell death, cellular proliferation, differentiation, inflammation, and viral replication promoting various aspects of immunity and inflammation • High level of TNF-α induces the inflammatory response, which in turn causes many of the clinical problems associated with autoimmune disorders such as rheumatoid arthritis • Reduction in the level of TNF-α new therapeutics to treat autoimmune disease like rheumatoid arthritis

  3. Neutralizing the biological effects of TNF-α in situations where over-expression of TNF-α causes negative clinical effects • Soluble forms of TNF receptor : trapping TNF-α in blood  Reduce the severity of many diseases caused by high level of TNF-α • Enbrel : TNF-α blocker approved for medical use - Developed by Immunex and approved by FDA in 1998 - Amgen acquired Immunex in 2002 - Engineered hybrid protein consisting of the extracellular domain of the TNF-α-R75 fused directly to the Fc region of human IgG - Dimeric soluble protein TNF-Receptor Fc

  4. Most widely used for treatment of disorders caused by excess TNF-α - Rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and juvenile rheumatoid arthritis. - Administered as a twice weekly via subcutaneous injection (25 in WFI) - Annual sale : $ 4.5 billion in 2010 • Competitors : Humira, Remicade (Monoclonal Ab) • Development of new version with greater potency - Protein engineering : structure-based rational design - Increased affinity /specificity - Stability in blood

More Related